logo

SNPX

Synaptogenix
--
--(--)
Market Open: --
--
--(--)
Post-Market: --

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About SNPX

Synaptogenix, Inc.

A clinical-stage biopharmaceutical company that developing new therapies for neurodegenerative diseases

Pharmaceutical
10/31/2012
06/07/2021
NASDAQ Stock Exchange
4
12-31
Common stock
1185 Avenue of the Americas, 3rd Floor , New York, New York 10036
--
Synaptogenix, Inc., was incorporated in Delaware on October 31, 2012. The company is a biopharmaceutical company with product candidates in preclinical and clinical development. The Company is primarily focused on developing a product platform based on a drug candidate called Bryostatin-1, synthesized from a natural product (bryostatin) isolated from marine invertebrate organisms for the treatment of Alzheimer's disease (" AD "), which is in clinical testing.

Company Financials

EPS

SNPX has released its 2023 Q3 earnings. EPS was reported at -0.03, versus the expected 0.00, missing expectations. The chart below visualizes how SNPX has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime